Prognosis of the intrahepatic cholangiocarcinoma after resection: hepatitis B virus infection and adjuvant chemotherapy are favorable prognosis factors
Open Access
- 1 January 2013
- journal article
- Published by Springer Nature in Cancer Cell International
- Vol. 13 (1) , 99
Abstract
The incidence and mortality associated with intrahepatic cholangiocarcinoma is increasing in many countries and documentation of disease outcome is sparse. The present study was undertaken to investigate the prognostic factors for intrahepatic cholangiocarcinoma (ICC) following surgical resection. The impact of pre-existing HBV virus infection and adjuvant chemotherapy on the overall survival was also evaluated. Clinical and pathological data were collected retrospectively from 81 patients undergoing surgery for ICC between 2005 and 2011, at The Henan Province Tumor Hospital and the First Affiliated Hospital of Zheng Zhou University. Survival and prognosis were analyzed using the Kaplan-Meier method and COX regression model. The population included 37 patients who were HBsAg + or anti-HBc+, 21 patients who were anti-HBs + positive and 18 patients who received adjuvant chemotherapy. The overall 1- and 3-year survival rates were 51% and 20%, respectively. The median survival was 12.2 months. Univariate analysis identified the following prognostic factors: HBV virus infection or HBV vaccine prior to resection (P = 0.017); adjuvant chemotherapy (P = 0.001); preoperative serum CA19-9 (> 200 U/mL; P = 0.015); GGT (> 64 U/L; P = 0.008), ALP (> 119 U/L; P = 0.01); lymph node metastasis (P = 0.005); radical resection (P = 0.021); intrahepatic metastasis (P = 0.015) and diabetes (P = 0.07). Multivariate analysis identified chronic HBV infection (RR = 0.583; P = 0.041), anti-HBs positivity (RR = 0.680; P = 0.050), adjuvant chemotherapy (RR = 0.227; P < 0.001), lymph node metastasis (RR = 2.320; P = 0.001), and intrahepatic duct stones (RR = 0.473; P = 0.032) as independent prognostic factors. HBV virus infection or HBV vaccination prior to resection, together with adjuvant chemotherapy, were independently associated with improved survival in patients undergoing surgery for ICC.Keywords
This publication has 23 references indexed in Scilit:
- Cytokine-induced killer (CIK) cell therapy for patients with hepatocellular carcinoma: efficacy and safetyExperimental Hematology & Oncology, 2012
- Hepatitis B virus infection: A favorable prognostic factor for intrahepatic cholangiocarcinoma after resectionWorld Journal of Gastroenterology, 2011
- Impact of hepatitis B virus infection on outcome following resection for intrahepatic cholangiocarcinomaJournal of Surgical Oncology, 2010
- Multiepitope peptide-loaded virus-like particles as a vaccine against hepatitis B virus–related hepatocellular carcinoma #Hepatology, 2009
- Relationship between pattern of tumor enhancement and clinicopathologic characteristics in intrahepatic cholangiocarcinomaJournal of Surgical Oncology, 2008
- Can the serological status of “anti‐HBc alone” be considered a sentinel marker for detection of “occult” HBV infection?Journal of Medical Virology, 2008
- Long-Term Presence of HBV in the Sera of Chronic Hepatitis B Patients with HBsAg SeroclearanceIntervirology, 2007
- CholangiocarcinomaThe Lancet, 2005
- The role of chemotherapy in cholangiocarcinomaAnnals of Oncology, 2005
- Results of surgical treatment for intrahepatic cholangiocarcinoma and clinicopathological factors influencing survivalBritish Journal of Surgery, 2002